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Abstract
In this paper, we critically explore the evolution and impact of the concept ‘bioeconomy’ as a descriptor 
and driver of diff erent scientifi c, technological, and policy initiatives in the life sciences. We unpack 
the diff erent ways bioeconomy has been framed – as an emergent, present, or sometimes promissory 
economic regime underpinned by particular socio-technical practices - by tracing how its use has 
evolved in diff erent disciplinary fi eld and  sectors. We also critically analyse three key reports that 
attempt to measure the size and contribution of the bioeconomy at regional levels. Our overarching 
questions are: What is the bioeconomy, how has it been used in diff erent fi elds, and how might it be 
best understood and valued both economically and politically? In answering these questions, we build 
on and contribute to critical scholarship in science and technology studies, particularly theoretical work 
on biovalue, commodifi cation, and assetisation; using this in conjunction with our empirical concept 
search and document analysis to contribute new knowledge and understanding of the bioeconomy’s 
past, present, and future.  
Keywords: bioeconomy, measurement, value, practices, promissory expectations, neoliberal
Article
Introduction
In this paper we explore the evolution and impact 
of the concept ‘bioeconomy’, as a descriptor of 
various scientific, technological, and policy ini-
tiatives in the life sciences. We unpack the diff er-
ent framings of bioeconomy, or more accurately 
‘bioeconomies’(Pavone and Goven, 2017), which 
are driving diff erent and often incompatible con-
ceptions of value and benefit. Our overarching 
questions are: what is the bioeconomy, how has 
it been used in different fields, and how might 
it be best understood and valued? This is not 
straightforward given the ephemeral and specu-
lative nature of the bioeconomy; the diverse dis-
ciplines within which the concept has acquired 
2salience, and the lack of consistency in the defi ni-
tion and categorization of its objects. The latter 
issue becomes critical when policymakers try to 
measure the size and overall contribution of the 
bioeconomy at national or regional levels. There 
has so far been no comprehensive and systematic 
attempt to trace the emergence of bioeconomy as 
a concept in diff erent disciplinary fi elds, and link 
this to emerging theories of value and valuation 
practices. This paper therefore makes an impor-
tant contribution to the social study of bioecon-
omy by using empirical evidence from a broad 
literature analysis to critically refl ect on bioecon-
omy’s diff erent framings, and address the policy 
implications for measurement and the attribution 
of value.
Bioeconomy appears to be an emergent, 
present, but also promissory economic regime 
built on the exploitation of old and new biological 
resources. What we mean by promissory is that 
much of its value is speculative; based on esti-
mations of future potential rather than current 
reality.  Some even describe it as a ‘neoliberal’ 
political project (Goven and Pavone, 2015). The 
concept is frequently cited within academic and 
policy literatures, yet it remains ambiguous and 
contested. The defi nition of bioeconomy, which 
depends on how its material objects and practices 
are included or excluded within classificatory 
regimes (Bowker and Star, 2000), also has socio-
political and economic consequences. Classifi ca-
tion systems and the standards they embody are 
usually adopted to create order and stability in 
an uncertain world. However, we will show in the 
case of bioeconomy that decisions about how to 
order and classify diff erent sectors and activities 
may obfuscate as much as they reveal. A certain 
ambiguity may be intentional, as policymakers 
must justify public investments in biotechnology 
and make good on powerful narratives of future 
promise. The bioeconomy might be consid-
ered ‘performative’ in the parlance of economic 
sociology (Callon et al., 2002). For example, 
governments and industry embrace life science 
innovation as a driver of economic and social 
prosperity, and this shapes the organisational 
structure and R&D options available to actors in 
the sector (Mittra, 2016).
There are nevertheless diff erent framings of 
the bioeconomy, and competing narratives about 
the contributions of the underlying science, 
technology, and material products. There is also 
recognition that multiple value(s) and valuation 
practices, beyond simply the economic, underpin 
the bioeconomy (Helgesson and Kjellberg, 2013; 
Lamont, 2012; MiƩ ra, 2016).  We suggest these 
multiple framings generate, within science/inno-
vation communities and amongst critical social 
scientists, both promissory (Borup et al., 2006) 
and more cautious narratives around value and 
benefi t. 
In this paper, we unpack the concept of bioec-
onomy and reveal the diff erent narratives of value, 
benefi t, and worth that underpin it. We begin by 
presenting fi ndings of a broad literature analysis 
we concluded in July 2018. Our aim was to trace 
the origins and use of the concept bioeconomy 
in the academic literature over time (from its fi rst 
use until the end of 2017) in the sectors of health/
medicine (red biotechnology), agriculture/food 
(green biotechnology), and energy/environment 
(white biotechnology). This gave us a sense of the 
concept’s provenance and evolution, and revealed 
salient diff erences in its defi nition and use. 
We then explore in depth diff erent framings 
of bioeconomy. We discuss the bioeconomy as 
simultaneously a neoliberal political project to 
improve national competitiveness, and a scien-
tifi c/technological project to meet global chal-
lenges such as climate change, food security, 
and health. The desire to generate new types of 
value from the monetisation of both old and new 
biological processes and technologies, in the 
context of these global challenges, illustrates the 
socio-political and economic issues at stake. Next, 
we critique three key reports (examples from the 
UK, US, and Europe) that attempt to measure the 
size and overall contribution of the bioeconomy 
using conventional metrics of value. We focus on 
these advanced economies because they have 
been at the forefront of innovation in life sciences 
and have most fully embraced the concept of 
bioeconomy in policy and practice. Given ambi-
guities around the bioeconomy concept, and its 
impact on diff erent industrial and policy sectors, 
in the fi nal section we consider the normative 
question of whether embracing a broader defi ni-
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3tion of value (beyond the economic) would help 
us better assess the bioeconomy’s future.  
In refl ecting on our empirical data, we draw 
critically on a range of theories that have emerged 
around biovalue, commodification, and asseti-
sation that we consider opens up possibilities 
for a more nuanced and broader approach to 
thinking about value and valuation processes. 
By opening up the concept of value to include 
the social practices of valuation, we suggest the 
bioeconomy can be explored in a more sophis-
ticated and interesting way. So on the one hand, 
we identify the tensions between framing and 
theorising the bioeconomy as a political, neolib-
eral project, or alternatively a strictly scientifi c/
technological project. On the other hand, we try 
to understand how diff erent theories of value and 
valuation (‘commodity’ versus ‘asset’ for instance), 
might help us gain purchase on the techniques 
of measurement that are being used in policy 
contexts to promote a particular ideal of bioec-
onomy. Given so much of the value ascribed to 
the bioeconomy is speculative, we also draw on 
the sociology of expectations and socio-technical 
imaginaries, where appropriate, to illuminate and 
refl ect on our data. 
Methods
We conducted a systematic literature search and 
concept analysis, which was completed in July 
2018, with the primary aim of identifying pub-
lished material that explicitly used the term ‘bio-
economy’ and its close variants. In addition to the 
main search term ‘bioeconomy/bio-economy’, we 
also searched ‘biobased/bio-based economy’ up 
until the end of 2017 to ensure we had data for 
a complete set of years. Many authors treat bio-
based economy and bioeconomy as synonymous, 
although Hausknost et al (2017) suggest techni-
cally bioeconomy refers to methods of converting 
raw material into bio-products, whilst bio-based 
economy refers to the raw material itself. We do 
not draw such a strict distinction in this paper. The 
published material covered peer-reviewed journal 
articles, some books and book chapters; and ‘grey’ 
literature, such as conference proceedings and 
abstracts, meeting reports, working papers, pres-
entations, technical notes, annual reports, bulletin 
articles, and governmental and non-governmen-
tal reports.
Our search was conducted using 16 databases: 
AMED; ASSIA (Applied Social Science Index and 
Abstracts); BioMed Central; BIOSIS Citation Index; 
Business Source Complete; CAB Abstracts; CINAHL 
Plus- Cumulative Index to Nursing and Allied 
Health Literature; Cochrane Library; Congres-
sional Record; Department of Health; Econlit; 
EMBASE; MEDLINE; IBSS (Social Science Premium 
Collection); Web of Science; and PubMed. The 
total number of hits across all databases, before 
we undertook a selection process and removed 
duplicates, was 5,313. Web of Science and IBSS 
generated the most hits with 1,780 and 1,352 
respectively. The initial search was applied to the 
full texts of the unsorted articles in each database, 
with the main inclusion criteria being that the 
documents include a discussion, or at least 
mention, of the primary search terms. The titles, 
publication dates, URLs, and, where applicable or 
possible, the specifi c research fi elds and abstracts 
of the selected documents were then copied into 
an Excel spreadsheet fi le. 
A total of 1,064 papers in the English language, 
published between 1992 (the fi rst time an article 
that met our search criteria appeared) until the 
end of 2017, were then selected on the basis 
of perceived relevance. All included the search 
term in either the title or abstract, indicating 
the importance attached to the concept. The 
academic papers, which constitute the majority 
of our selected material, covered research areas 
from the natural, social, and applied sciences; and 
academic disciplines and interdisciplinary fi elds 
such as biology, chemistry, economics, law, inno-
vation studies, geography, sociology, science and 
technology studies; education, medical sciences, 
materials science, environmental sciences, and 
agricultural sciences. Non peer-reviewed and 
more generalist documents, including policy-
oriented documents and reports were also 
identifi ed and categorized separately from the 
academic papers. Our fi nal categorization sought 
to diff erentiate peer-reviewed  academic papers 
from the natural sciences and the social sciences 
(our primary focus) and this broader gray litera-
ture, where we prioritized offi  cial governmental 
and non-governmental reports. 
Mittra & Zoukas
4The purpose of the search was to reveal and 
sensitise us to how the concept of bioeconomy 
had been used over time, in diff erent academic 
fields, to complement our subsequent inves-
tigation of how the concept has been framed 
by different constituencies and stakeholders. 
Following the creation of the spreadsheet, Mittra 
(Lead Author) read through the abstracts of all 
articles, and scanned the full texts in some cases, 
to categorize the papers into the broad fields 
of white (industrial biotechnology/sustainable 
energy), red (health/pharmaceuticals), green 
(agriculture and food), and blue biotechnology. 
Blue refers to cases where it was not clear that 
the paper contributed entirely or mainly to one 
fi eld. Blue biotechnology conventionally refers 
to marine biotechnology/aquaculture, but given 
we found so few articles in this specifi c fi eld, we 
classifi ed them alongside green biotechnology, 
reserving the blue category for those articles 
lacking specifi city. In subsequently categorizing 
the papers according to whether they were from 
the social sciences, natural sciences, or ‘other’, 
we were able to identify salient patterns over 
time. This exercise was suffi  cient for our purpose 
of providing an overview of how the concept 
evolved in the literature over the given time 
period. We could have categorized the papers 
further into multiple sub-disciplines, but it is not 
clear how useful or accurate this would have been. 
Others have provided more detailed and compre-
hensive systematic reviews using citation data at 
the disciplinary level  (Bugge et al., 2016; Golem-
biewski et al., 2015), and we refer to this work and 
its data to complement our own analysis.
Certain caveats are necessary to clarify the 
limitations of our method and the knowledge 
claims we can make. First, we note that there is 
an inherent subjective element to the choice 
of search criteria and the categorization of the 
papers. In many cases, the distinction between 
social science and natural science is blurred, e.g. 
environmental science, which embraces both 
natural and social scientifi c approaches. The same 
is true for the distinction between white and 
green biotechnology. For instance, where biotech-
nology is used to improve crop development for 
biofuels, this could reasonably be classed as both 
green and white biotechnology.  There will always 
be some overlap at the boundaries of disciplines 
and fi elds, so some of our category decisions were 
inevitably subjective. Alternative classificatory 
decisions could have been justifi ed. In those cases 
where a paper contributed to more than one fi eld, 
a decision was made to choose what we judged to 
be the predominant fi eld. If the paper was contrib-
uting equally to more than one fi eld, or where a 
decision on predominant fi eld could not be ascer-
tained, we categorized the paper as ‘blue’. The 
latter were mainly policy-oriented documents or 
reports, as well as broader review pieces.
Second, the range of databases chosen, and 
the search terms used, may not have captured 
all articles addressing salient themes relevant 
to the bioeconomy. Many more articles would 
have been captured if we had included ‘biotech-
nology’, ‘life sciences’, or ‘genomics’ in our search 
(all of which discuss similar themes). However, 
given our primary interest was in the evolution 
and use of a new term called ‘bioeconomy’ or 
‘bio-based economy’, as a signifi er of novel activi-
ties and practices, limiting the search criteria was 
justifi ed. Our results are broadly consistent with 
the fi ndings of those who have conducted biblio-
metric/citation research on bioeconomy. In the 
following section, we summarise the key fi ndings 
from our literature analysis, before unpacking and 
critically exploring the concept and its framing in 
more detail. 
Tracking Use of the Term 
Bioeconomy Over Time: Key 
Findings from Literature Analysis
Our fi ndings reveal that the use of the term bio-
economy, or biobased economy, has increased 
over time, particularly from 2006 onwards, as 
illustrated in Figure 1. Before 2004, only 15 articles 
met our fi nal inclusion criteria. Since then there 
has been a steady increase in the total number 
of articles that explicitly reference the term in the 
title or abstract, with a particularly high number in 
the period 2014-2017. We surmise that the Organi-
sation for Economic Cooperation and Develop-
ment’s (OECD) 2006 report The Bioeconomy to 
2030: Designing a Policy Agenda (OECD, 2006), 
which we disucss later, became a key document 
that helped drive the salience of the concept and 
played an important role in popularising the term 
in a variety of academic disciplines.
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5Figures 2 and 3 show the number of 
publications by broad disciplinary area (social 
science, science, and policy/non peer-reviewed 
grey literature) and by fi eld/sector respectively. 
Figure 4 displays the publications by fi eld in 
each disciplinary category to show diff erences 
in how social science and natural sciences, in 
particular, have prioritised certain approaches to 
bioeconomy. 
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Figure 1. Total Number of Publications by Year Using the Term Bioeconomy or its Variants.
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Figure 3. Publications by Field/Sector.
Figure 4. Publications by Field in Each Category.
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7In terms of broad disciplinary area (Figure 2) we 
can see that, apart from 2016 and 2017, slightly 
more peer-reviewed articles in our fi nal selection 
came from the social sciences, rather than the 
natural sciences. However, we note our earlier 
caveat that the boundaries can be blurred in 
some cases. Nevertheless, the patterns of growth 
in the social science articles do not neatly follow 
those of the policy and science-based articles, 
which suggests that the disciplines have their 
own momentum. We did not attempt to classify 
the sub-disciplines within each general fi eld, but 
Bugge at al. (2016) have in their comprehensive 
citation analysis. They found that amongst the 
broad diversity of disciplines in the sciences that 
have engaged with the term bioeconomy, the 
natural and engineering sciences have taken a 
predominant role, with the Web of Science cate-
gories ‘Biotechnology and Applied Microbiology’ 
and ‘Energy and Fuels’ constituting a 25% share 
of the total papers that the authors identifi ed. 
This confi rms our own search results from Web of 
Science.
However, the publications by general field/
sector data (Figure 3) is more revealing. From 
2006, we can see that in each year most of the 
publications were within the category white 
biotechnology, followed by blue (non-specifi c), 
then green biotechnology, and fi nally red biotech-
nology. So where it was possible to clearly identify 
a lead sector, white biotechnology was by some 
margin the one most likely to generate articles 
explicitly referencing bioeconomy. If we then 
look at publications by sector in each discipli-
nary category (Figure 4), we see that for natural 
sciences, white biotechnology is a clear leader 
with 301 papers, followed by green biotechnology 
(69), then blue (26), and fi nally red (5). For social 
sciences, white was still predominant (214 papers), 
but blue (133), green (85), and red (67) biotech-
nology were also far more likely to be represented 
than for the scientifi c disciplines. For our Policy/
Misc fi eld, white and blue biotechnology tended 
to be most common, with green biotechnology 
not far behind, but red biotechnology was very 
low with only 5 documents. We do note that the 
Policy/Misc category is not as comprehensive as 
the social and natural sciences categories. This 
is because we had to be far stricter on inclusion 
criteria (official and significant reports) as this 
category could have included press releases, 
news items, conference posters etc that would 
have created an unmanageable and not particu-
larly useful dataset. As such, the total number of 
documents in this category was small in compar-
ison to the other categories, which are our main 
focus. 
Of those papers that were in the fi eld of red 
biotechnology, or the non-specifi c blue category 
(Figure 4), it is a signifi cant fi nding that these 
were predominantly social science papers, which 
suggests that social scientists’ understanding of, 
and intellectual interest in, the bioeconomy does 
not align with that of the natural scientists. To be 
sure, there is still high engagement with white 
biotechnology, as there is in the natural sciences. 
We should clarify here that most of the social 
science papers discussing white biotechnology 
were generally environment focused (risk assess-
ment, economic analyses, survey research etc) in 
the context of biofuel development or sustainable 
agriculture/forestry. This was an area where the 
boundary between the social and natural sciences 
is often blurred, as we explained earlier. 
Our data suggests, as we elaborate in the 
following section, that when scientists, and to 
some extent policymakers, mention bioeconomy, 
they are mainly talking about using biological 
processes in new ways to drive sustainable 
energy production, or contribute to environ-
mental protection. It is this that is seen to consti-
tute a new economic regime. Again, this fi nding 
is supported by the work of Bugge et al. In their 
list of science journals with papers citing bioec-
onomy, the top four were: ‘Biofuels, Bioprod-
ucts & Biorefi ning-biofpr’ (27 papers); ‘Journal of 
the American Oil Chemists Society’ (15 papers); 
‘Biomass and Bioenergy’ (18 papers); and ‘Journal 
of Cleaner Production’ (12 papers). The journal 
‘Green Chemistry’, despite only having 3 papers 
that used the concept, also generated the highest 
number of citations at 1056. 
What we see in our data, and that of Bugge et 
al, is a complex picture in which a broad range of 
disciplines and fi elds are using the concept bioec-
onomy, but the peer-reviewed scientifi c literature 
tend to limit its defi nition to the use of industrial 
biotechnology to meet growing energy needs 
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8in a more sustainable way. This, as we discuss 
in more detail later, mirrors many of the early 
policy approaches to the bioeconomy (such as 
the OECDs), where new economies of the future 
based on sustainable bio-based products have 
become part of the collective policy imagination, 
which we can describe as sociotechnical imagi-
naries (Jasanoff  and Kim, 2009).  This is interesting 
given many social science articles, particularly 
those critical of the commodifi cation processes 
and neoliberal assumptions that prefigure 
an expectant bioeconomy,  tend to reference 
examples from red or green biotechnology to 
support their claims. Social scientists’ under-
standing and interest in the bioeconomy does 
not therefore align with that of natural scientists. 
So there are multiple framings and meanings 
attached to the concept of bioeconomy, which 
have material consequences for the ways in which 
R&D policy is structured, shaped, and understood. 
It is to these that we now turn. 
Multiple ‘Framings’ and 
Theories of Bioeconomy and 
their Material Consequences
Our analysis revealed that the concept of bio-
economy has been defi ned multiple ways in dif-
ferent contexts. Although in use before 2004, 
bioeconomy only gained traction and politi-
cal salience from 2006, specifi cally as a term to 
describe emerging or nascent economic activi-
ties and opportunities from ‘new biology’; that is 
the advances in molecular biology that acceler-
ated in the 1990s and promised to revolutionize 
the industrial sectors of health, food, and envi-
ronment (Wield, 2013; Wield et al., 2013). In an 
important 2006 report, The Bioeconomy to 2030: 
Designing a Policy Agenda, the OECD formally 
defi ned the bioeconomy as:
… the aggregate set of economic operations in 
a society that use the latent value incumbent 
in biological products and processes to capture 
new growth and welfare benefi ts for citizens and 
nations. These benefi ts are manifest in product 
markets through productivity gains (agriculture, 
health), enhancement eff ects (health, nutrition) 
and substitution eff ects (environmental and 
industrial uses as well as energy); additional 
benefi ts derive more eco-effi  cient and sustainable 
uses of natural resources to provide goods and 
services to an ever growing population. (OECD 
2006: 1)
In an updated 2009 report, the OECD stated:
…the bioeconomy can be thought of as a world 
where biotechnology contributes to a signifi cant 
share of economic output. The emerging 
bioeconomy is likely to be global and guided 
by principles of sustainable development and 
environmental sustainability … A bioeconomy 
involves three elements: biotechnological 
knowledge, renewable biomass, and integration 
across applications. (OECD 2009: 22)
These quotations provide a broad definition of 
bioeconomy, where new technological practices 
and economic regimes will extract latent value 
from natural biological processes to both meet 
sustainability goals and promote national compet-
itiveness. The idea of latent value, which assumes 
biological objects and processes have both inher-
ent and ascribed value, is shared by a set of schol-
ars who talk about ‘bio-value’ and new processes 
of ‘commodification’ (Cooper, 2008; Novas and 
Rose, 2000; Parry, 2007; Sunder Rajan, 2006). These 
authors focus on new and emergent forms of 
‘biovalue’, and are interested in how objects and 
practices that we might intuitively consider to be 
outside the conventional capitalist economy (e.g 
natural resources) become monetized and seen as 
a source of diff erent forms of economic value. In 
his review of the concept ‘neoliberalism’, Harvey 
(2006) also talks about how a fundamental feature 
of neoliberalism is that it opens up new fi elds for 
capitalist accumulation in areas previously seen in 
terms of a public goods framework, such as popu-
lation genetic resources. Brown’s (2013) work on 
the contradictions in use and exchange value in 
the cord-blood economy also highlights some of 
the challenges of these diff erent conceptions of 
value. 
The uneasy alignment of capitalism and 
biotechnology research, and the diff erent business 
models and value systems that are coming to 
defi ne contemporary life science-based industri-
alisation (Wield et al., 2015), has been critiqued 
by many Science and Technology Studies (STS) 
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9scholars and bioethicists. The commodifi cation 
aspects of the bioeconomy, and the co-produc-
tion of so-called ‘biovalue’ (Cooper, 2008; Rose, 
2001; Sunder Rajan, 2006; Waldby, 2002) is one 
approach. Others have contemplated the broader 
technical processes of accounting and assetisa-
tion that underlie the virtual bioeconomy and its 
valuation practices (Birch, 2007; Birch 2017; Birch 
and Tyfi eld 2013). These authors have unpacked 
the underlying assumptions of both practitioners 
within the bioeconomy, however defined, and 
critics who have sought to exceptionalise novel 
forms of biological material and ascribe it inherent 
value. Yet others have questioned the basis of 
what they suggest are promissory commercial 
narratives about a ‘biotechnology revolution’ 
(Hopkins et al., 2007), which become aligned 
with an imagined techno-future where current 
global challenges are ameliorated. Of course, 
some authors note that fi rms often consider more 
pessimistic scenarios, alongside their promissory 
claims, when, for instance, conducting foresight 
studies (TuƩ on, 2011).  
The theory of bio-value itself has also been 
critiqued by some scholars (Birch and Tyfield 
2013; Birch 2017) for not addressing the ‘asset-
based’ aspects of the bioeconomy, and instead 
valorizing what are considered to be highly novel 
commodity aspects, which we discuss in more 
detail in the fi nal section. Talk of ‘latent value’, 
which sees untapped potential in both conven-
tional and new biological material, also tends 
to prioritize the sustainable, natural resource 
management aspects of the bioeconomy (white 
biotechnology), which we showed is predominant 
in the science and policy literatures. 
The second quotation from the OECD more 
explicitly frames the bioeconomy as a vision of 
how advances in biotechnology can contribute 
to economic output and growth. Here, there 
is a clear alignment of investments in biotech-
nology research, capital,  and perceived national 
competitiveness. This framing is also evident 
in the European Commission’s approach to 
the bioeconomy, which has sought to make 
substantial investments in research addressing 
topics relevant to the sustainable production of 
new products based on biomass. This was a key 
component of the European Commission’s 2012 
Bioeconomy Strategy (European Commission, 
2012), which we discuss later. 
The accounts of policy-oriented organisa-
tions, captured in our literature search, tend 
to focus on the sustainable food and energy 
sectors and emphasise the need to respond to 
climate change and food security. As Hausknost 
et al confirm in a recent paper (Hausknost et 
al., 2017), ‘green growth’ through the industrial 
application of biotechnology has emerged as 
an important bioeconomy vision, or perhaps a 
socio-technical imaginary. So a predominant 
narrative is about creating new markets for indus-
trial biotechnology, which recognizes opportuni-
ties to capture latent value in natural biological 
processes and accelerate the transition from a 
fossil-fuel economy. There is additional interest in 
the potential economic benefi ts of sustainable 
manufacturing and processing industries. Some 
regard this definition, which is rooted in the 
concept of ‘biovalue’ discussed above, as most 
meaningful and practical from a policy perspec-
tive (Brunori, 2013). Proponents claim multiple 
benefi ts, including the creation of high value jobs, 
lower emissions, energy security, reduction of 
dependence on subsidies, a growing agricultural 
sector, and even in some cases the stabilization of 
rural communities. This promissory and expectant 
discourse is part of the future-oriented vision of 
the European Commission as well as organisa-
tions like the OECD. We focus on these powerful 
policy actors precisely because they have played 
a signifi cant role in the performative aspects of 
bioeconomy; shaping the nature of R&D practices 
and the metrics used to ascribe diff erent forms of 
economic and non-economic value. 
There is a strong neoliberal fl avor to some of 
these framings of bioeconomy (linking global 
problems, science, and economic growth, and 
monetizing what might be considered public 
resources, for instance). This was perspicuous in 
President Obama’s 2012 National Bioeconomy 
Blueprint, when it stated: ‘Technological innova-
tion is a signifi cant driver of economic growth, and 
the U.S. bioeconomy represents a growing sector 
of this technology-fueled economy’ (The White 
House, 2012: 1). We do not take a strong normative 
stance on what many social scientists pejoratively 
claim are the neoliberal underpinnings of the 
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bioeconomy. We are not, for example, seeking to 
criticize policy organisations that link bioeconomy, 
sustainability and economic growth. Neverthe-
less, we do fi nd it interesting that the notion of the 
bioeconomy as a driver of sustainable growth, and 
as having unlimited potential to deliver economic 
and societal benefi ts, has been the subject of such 
criticism and debate. While many social scientists 
suggest that a neoliberal philosophy is driving 
policy, perhaps more importantly they argue this 
is ultimately based upon often unjustifi ed specu-
lative value propositions and ideologies. So there 
is a credibility gap between an imagined future 
and current reality. Cooper (2008), for instance, 
argues that the emergent biotechnology indus-
tries cannot be diff erentiated from neoliberalism’s 
rise as a dominant political philosophy:
 The biotech revolution … is the result of a whole 
series of legislative and regulatory measures 
designed to relocate economic production at 
the genetic, microbial, and cellular level, so that 
life becomes, literally, annexed within capitalist 
processes of accumulation.(Cooper 2008: 19)
Styhre and Sundgren (2011) describe the bioec-
onomy as the ‘economic regime of accumulation 
where technoscientifi c know-how developed in 
the life sciences is capable of making the lived 
body a principal surface of economic value 
creation’(Styhre and Sundgren 2011: 3) For these 
authors, bioeconomy and neoliberalism are inti-
mately aligned, with the utility and vitality of life 
itself subject to the vagaries of speculative com-
modification (Sunder Rajan, 2006). Birch (2007) 
goes further in describing the bioeconomy as 
a ‘virtual abstraction’ of economic practices in 
which benefit and potential ‘…are intertwined 
concepts … repeated numerous times through-
out this policy literature, which essentialises and 
naturalises the claims made about its innovative 
potential’(Birch 2007: 89). In an earlier article, 
Birch (2006) suggested that economic represen-
tations and practices are legitimation devices for 
policy, which generate self-fulfi lling prophesies. 
This is particularly evident in the context of claims 
about the bioeconomy’s importance for national 
competitiveness. 
In all these policy examples, and their critiques, 
the bioeconomy is framed mainly as a political 
and economic project to support new forms of 
capitalism, rather than a scientifi c or technolog-
ical endeavor. But what does it mean to say the 
bioeconomy is a political project? What does this 
framing tell us about the nature of the scientifi c 
practices that are both driving and being driven 
by the machinations of policy, government, 
and industry? These arguments need further 
unpacking. 
The Bioeconomy as a Political Project
Peterson and Krisjansen draw on the sociology of 
science and economic sociology to examine the 
sociopolitical signifi cance of what they argue are 
promissory discourses enveloping discussions of 
the bioeconomy (Petersen and Krisjansen, 2015). 
They suggest these discourses have an impor-
tant performative role in modern biopolitcs. 
Activities that in the past might have been treated 
separately in policy, such as the different bio-
technology sectors and industries around health, 
agriculture, and energy/environment, are now 
viewed under the general rubric of bioeconomy. 
The authors question the validity of some of the 
assumptions underlying these promissory dis-
courses, as well as the logic of lumping disparate 
scientifi c, technological, and industrial activities 
and sectors within an all-embracing category. 
However, it is the political nature of the bioec-
onomy that is implicit in their analysis, which 
is shared by Goven and Pavone who, in their 
Polanyian analysis, describe it as a promissory 
construct to “…induce and facilitate some actions 
while deterring others; most explicitly it is meant 
to bring about a particular set of political-institu-
tional changes that will shape the parameters of 
possible future action” (Goven and Pavone 2015: 
1). Although not doubting the science and policy 
communities’ noble intent to use biotechnology 
to solve global challenges; the authors describe 
the world in which the bioeconomy operates as 
imagined; one where “… human and environ-
mental disasters are averted because a particular 
political-institutional configuration facilitated 
the development of profitable technological 
solutions” (Goven and Pavone 2015: 4). In a more 
recent paper, the authors argue: “Bioeconomy 
strategies position the bioeconomy as key to 
‘global competitiveness’, while the need for ‘global 
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competitiveness’ is taken for granted” (Pavone 
and Goven 2017: 7). They suggest this framing 
displaces alternative approaches that seek to 
address structural and endemic aspects of the 
global challenges facing society, and ultimately 
sustains the status quo. This view is consistent 
with Harvey’s (2006) account of neoliberalism’s 
damaging ‘creative destruction’, which emerges 
from the process of commodifi cation and privati-
zation, and an obsession with econometrics. 
Similarly, Doezema and Hurlbut (2017) suggest 
dominant visions of the bioeconomy – i.e. as a 
political, neoliberal project in which the market 
is valorized above all else – refl ect an ‘imaginary 
of governance’. That is, they “…construct techno-
science as the agent capable of enhancing social 
well-being, and outline the corollary political 
commitments that are prerequisite for desirable 
technological futures” (Doezema and Hurlbut 
2017: 50). Again, the argument here is that a 
promissory vision of a successful bioeconomy 
is suff used with assumptions and expectations 
about biotechnology’s transformative potential. 
These authors see the OECD’s Bioeconomy to 
2030 Report and the US Bioeconomy Blueprint, for 
example, as exemplifying the aspirational political 
vision of technoscience as the ultimate solution 
to society’s problems. In so doing, such reports 
‘draw upon and crystalize  widely shared notions 
of the rights, roles, and responsibilities of political 
subjects in relation to both science and the state’ 
(Doezema and Hurlbut 2017: 50). 
Hilgartner uses the term ‘anticipatory enter-
prises’ to describe organisations like the OECD and 
the European Commission. Such organisations 
are engaged in technological foresight, in which 
future-oriented expectations and imaginaries of 
technoscience are central. However, Hilgartner 
suggests that they are not simply seeking to antic-
ipate the future. They are also seeking to shape or 
transform it. (Hilgartner 2007: 382.)
These powerful policy drivers to build a sustain-
able bioeconomy, whether or not their promissory 
visions are realistic, have an impact on research 
strategy and organizational practices, which is 
why we describe them as having a performa-
tive function. It is also why we consider them 
important objects of study. The hopes and expec-
tations that are embedded within the reports of 
national and international policy institutions, 
governments, and commercial organisations, are 
not simply rhetoric. They have a material impact 
on what areas of science get funded and what 
kind of research is valued.
The bioeconomy, we suggest, is both a political 
and a scientific/technological project, in that 
old and new science and technology is being 
exploited to transform society and economy. 
When a particular conceptualization of bioec-
onomy becomes attached to innovation policy 
and strategy, this shapes behaviour in the 
communities that are responsible for developing 
and applying biotechnology research. Although 
the scientifi c community may see its activities and 
practices through the prism of basic science and 
technology, innovation policy is shaped by social 
and political exigencies. 
As our analysis revealed, most of the scientifi c 
papers used bioeconomy to frame a set of scien-
tifi c and technological challenges. Moreover, this 
literature refl ected a vision of the bioeconomy as 
a facilitator of white biotechnology; using micro-
organisms or enzymes to create new biological-
based products to meet sustainability objectives 
or to improve global agricultural production 
systems for food security. This mirrors the policy 
approaches to bioeconomy over the past decade. 
As McCormick and Kautto (2013: 2594) argue, 
“The principal products of the bio-economy are 
bio-based products and bioenergy”, so this is 
where the primary focus has been, as evidenced 
by Golembiewski et al (2015) in their biblio-
metric  analysis of the bioeconomy landscape 
(Golembiewski, Sick, and Bröring 2015: 309). A 
large portion of our selected articles from the 
science and policy fi elds emphasized this specifi c 
challenge. So what is the impact of these framings 
in terms of the policy agendas that are actually 
shaping the contribution of life science-based 
research to the economy? There are important 
questions about the size of the bioeconomy and 
where is it heading. To address these, we now 
discuss attempts to measure the activities and 
practices constituted within the bioeconomy, 
and critically analyse this in the context of the 
theories and concepts of biovalue and promissory 
discourses outlined.
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Value(s), Valuation Metrics and 
Practices in the Bioeconomy
The way the bioeconomy concept is driving policy 
agendas and shaping industrial strategy raises 
questions about promissory value and valuation 
practices. This becomes salient when we look 
at attempts by policymakers and innovators to 
measure the size and growth potential of national 
and regional bioeconomies. As Hilgartner (2007) 
argues, realising the OECD’s policy vision of an 
international bioeconomy requires a means to 
align the formal defi nition of bioeconomy (aggre-
gate set of economic operations built on biologi-
cal products etc.) with the everyday activities and 
practices that this abstract defi nition is used to 
represent. This:
… is not simply a matter of one-way reifi cation, 
in the sense of treating an abstraction as if 
it had concrete existence; it is a process of 
iterative alignment that also involves making 
the abstraction more concrete by constructing 
techniques and institutional machinery capable of 
persuasively representing the activities (Hilgartner 
2007: 385).
Importantly, estimates of the economic contribu-
tion of activities and practices constitutive of the 
bioeconomy depend on the use of these calcula-
tive devices and techniques, which have political 
and commercial implications. Here, we look at 
three case examples; one from the UK, one from 
the US, and another at a pan-European level.
Measuring the UK’s Bioeconomy
A recent report by Capital Economics, TBR, and 
E4tech, on behalf of the UK’s Biotechnology and 
Biological Sciences Research Council (BBSRC) and 
the Department for Business, Innovation and 
Skills (Bauen et al., 2016), presents a sophisticated 
evidence-based review of the contribution of the 
bioeconomy to UK growth and competitiveness. 
Like the OECD, this report defi nes the bioeconomy 
as encompassing “all economic activity derived 
from bio-based products and processes”, and sug-
gests that: “These contribute to sustainable and 
resource-effi  cient solutions to the challenges we 
face in food, chemicals, materials, energy pro-
duction, health and environmental protection” 
(Bauen et al., 2016: 3). Interestingly, the report 
clarifi es that the bioeconomy builds on activities 
that involve ‘transformative processes’ -as well as 
their related upstream and downstream activities 
- around biological resources. This includes both 
conventional activities like growing crops and 
rearing livestock, as well as advanced bio-based 
products. 
So the report is interested in both new, 
advanced biological innovations, as well as any 
activity or process that involves manipulation or 
conversion of biological resources into products 
that contribute to the economy. This broad defi ni-
tion increases the scale and potential value of the 
UK bioeconomy. The report states:
The transformational bioeconomy comprising 
agriculture and fi shing, forestry and logging, 
water and remediation activities, food products 
and beverages and industrial biotechnology and 
bioenergy accounts for 3.5 per cent of gross value 
added in the United Kingdom (£56.0 billion in 
2014), which is a little more than the wholesale 
trade and more than double the fi gure for the 
crude petroleum and natural gas extraction and 
mining industries (Bauen et al., 2016: 5)
When adding upstream and downstream activi-
ties related to this bioeconomy, the report states 
that £220 billion is generated in gross value 
added, supporting 5.2 million jobs. Furthermore, 
it suggests the UK bioeconomy plays a major 
role in attracting inward investment. The report 
states that in recent years the bioeconomy has 
performed much better than the economy as a 
whole, having previously lagged behind. In terms 
of European competitiveness, the report argues 
that the UK bioeconomy is smaller than in some 
other major European countries, in terms of gross 
value added, but that if contributions from agri-
cultural activities were removed from the analysis, 
the UK bioeconomy is larger than Italy and Spain, 
and comparable to France. So here we see how 
measurements of growth potential (the report 
estimates that output could grow by 13% in the 
coming years) and international comparisons, 
which are important in policy contexts to align 
innovation, investment, and wealth creation; can 
signifi cantly shift depending on the inclusion and 
exclusion criteria. 
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Overall, this is a sophisticated report in that 
it provides sector-by-sector data on jobs and 
economic activity, and does not limit the analysis 
to white biotechnology, so it is adopting a broad 
defi nition of bioeconomy. However, it does not 
enable us to estimate the specifi c contribution 
of the newer and advanced biotechnological 
innovations, which begs the question of whether 
by being so inclusive, such measurements and 
estimations render the bioeconomy concept 
meaningless. Nevertheless, as a political project, 
the bioeconomy concept is clearly successful in 
appropriating economic activities and generating 
the promise of future value  – albeit comparative  - 
and the creation of jobs.  
Contribution of the US Bioeconomy
In the US, a report by the Bioindustry Association 
(BIO), a trade body, and Battelle, a not-for profi t 
R&D organisation, assessed the contributions 
made by fi ve broad bioscience-based sectors to 
the US economy (BaƩ elle et al., 2014). This report 
attempts to measure the contribution of certain 
bio-based sectors to the US economy, using data 
on sectoral employment and wages, R&D expen-
ditures, patents, and various kinds of conventional 
performance metrics. Like the BBSRC report, the 
most revealing aspect is what is included and 
excluded in the analysis. The fi ve sectors analysed 
were: ‘Agricultural Feedstock and Chemicals’; 
‘Drugs and Pharmaceuticals’; ‘Medical Devices and 
Equipment’; ‘Research, Testing and Medical Labo-
ratories’; and ‘Biosciences-Related Distribution’. 
Overall, the report presents a sanguine picture of 
the success of the bio-industries, stating “… bio-
science in the 21st Century has been a consistent 
producer of innovation-driven economic growth 
– generating jobs, income and output growth for 
those regional economies with key bioscience 
assets” (BaƩ elle et al. 2014: 2). 
The data presented show, like the BBSRC report, 
that the bioscience industries have responded 
better to the fi nancial crisis of 2007/2008 than 
private industry as a whole. The sector has 
continued to grow in terms of job creation. 
Furthermore, in terms of gross economic output, 
the report reveals that in all fi ve sectors nominal 
output continued to expand signifi cantly from 
2001-2012.  The report also shows that, apart 
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from R&D funding, which had been relatively fl at 
until 2014, most other metrics of value (employ-
ment, patents, venture funding etc.) had risen. 
However, it is important to note that job growth 
had declined in the drug development and agro-
biotechnology sectors. Nevertheless, we again 
return to the critical issue of what is included and 
excluded in the selection of activities, practices, 
and material objects that are presented as consti-
tutive of the bioeconomy. For example, in the 
‘Drugs and Pharmaceuticals category’, no distinc-
tion is made between advanced bio-based R&D 
and conventional small-molecule drug develop-
ment, so the specifi c contribution of biology to the 
health-related bioeconomy cannot be extracted 
from the analysis. One might legitimately ask 
if this aspect of drug innovation is more or less 
valuable as a driver of employment, economic 
growth, and indeed patient health and wellbeing, 
than conventional drugs? However, this question 
cannot be answered by the data provided in the 
report. 
An editorial in the journal Nature Biotech-
nology (Nature Biotechnology, 2014), provided 
a nice critique of this report on the grounds that 
the size of the bioeconomy is a constantly moving 
target precisely because analysts are too inclusive 
in some cases, and not inclusive enough in others. 
It is therefore impossible to make accurate and 
meaningful judgements of its scale and scope. 
For example, the report includes fi rms that manu-
facture fertilizer in its ‘agricultural, feedstock 
and chemicals’ sector, when it might have been 
more justifi able to categorise this as part of the 
chemicals rather than biotech industry. This is 
similar to our earlier argument about the lack of a 
clear distinction between chemical and bio-based 
drug development. In terms of the “medical 
devices sector”, the editorial argues the report 
accepts the US Department of Labor’s defini-
tion, which includes “… manufacturers of clamps, 
canulae and bone drills as well as syringes, knives 
and medical thermometers” (Nature Biotechnology 
2014: 598). These are not activities and products 
one would naturally associate with innovative life 
sciences, yet they are being captured in analyses 
of the economic contribution of the bioeconomy. 
The Nature editorial reserves the greatest 
criticism for the categories excluded from the 
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analysis, and the employment data is particularly 
interesting. “…the report tallies up the number of 
bioscience patents …. but does not enumerate 
bioscience patent lawyers. It notes the gradual 
increase in venture capital spending, but does 
not count up venture investors” (Nature Biotech-
nology 2014: 598). Furthermore, the report does 
not factor the increase in number of jobs within 
regulatory agencies and reimbursement agencies, 
as well as those in health insurance companies 
and reimbursement agencies, which are more 
relevant to the bioeconomy than jobs associated 
with conventional medical device development, 
or manufacture of chemicals for the agricul-
tural sectors. Indeed, the size of the bioeconomy 
could turn out to be much larger than the report 
suggests, if all these additional jobs and activities 
were included, and others excluded.
Scepticism of many conventional attempts to 
capture the economic contribution of the bioec-
onomy is shared by Carlson (2016). Summarising 
the problem, he states:
Current understanding of the biotech sector 
is hampered by inconsistencies in usage and 
defi nition of ‘biotechnology’ and ‘bioeconomy’ 
… These words may be  used in reference only 
to pharmaceuticals (or biopharmaceuticals, 
or biologics, depending on one’s defi nition), 
genetically modifi ed (GM) crops, or public 
companies whose primary revenues rely on 
biological technologies, thereby muddling an 
integrated description of the industry … Beyond 
linguistic imprecision, a lack of data resulting 
from inadequate characterization of the economy 
hampers any assessment of the economic size and 
scope of biotech. (Carlson 2016: 247).
Carlson proceeds to point out that even in the US, 
which dominates global biotech, there is no offi  -
cial means to distinguish biological from non-bio-
logical technologies and products. For example, a 
chemical manufactured using biologics is treated 
similarly to one produced from fossil petroleum. 
The former may displace the latter ‘on the basis of 
price or preference, yet revenues now accrue to a 
category that includes petrochemicals.’ (Carlson 
2016: 247)  So under the present system of clas-
sifi cation, revenue accruing from a novel biomole-
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cule could, according to Carlson, be misattributed 
to fossil fuels.
The Value of the European Bioeconomy
As a key region promoting the bioeconomy, the 
European Union’s 2012 ‘Bioeconomy Strategy’ 
and its 2017 review (European Commission, 2017) 
touts the importance of a market estimated in 
2009 to be worth over 2 trillion euros and respon-
sible for 20 million jobs  (M’Barek et al, 2014). The 
key objecƟ ves outlined in the 2012 strategy are; 
1) ensuring food security; 2) managing natural 
resources sustainably; 3) reducing dependence on 
non-renewables; 4) climate change miƟ gaƟ on and 
adaptaƟ on; and 5) creaƟ ng jobs and ensuring EU 
compeƟ Ɵ veness (European Commission, 2012). In 
a recent  review of this strategy (European Com-
mission, 2017), the Commission suggested the pol-
icy context within which the bioeconomy operates 
has signifi cantly changed since the 2012 strategy 
was developed (parƟ cularly around sustainability 
goals). This may require a refocus on key elements. 
However, it noted there had been success on 
some of the deliverables of the original strategy, 
particularly around the mobilization of funding 
for research and innovaƟ on, under Horizon 2020, 
and the development of standards for bio-based 
products, as well as key contribuƟ ons to European 
employment and income generaƟ on.
A recent paper takes the Commission’s strategy 
and defi nition of bioeconomy and attempts to 
define a methodology to quantify two bioec-
onomy indicators  - turnover and employment 
– using Eurostat data (Ronzon et al., 2017). This 
work was conducted in collaboration with the 
European Commission’s Joint Research Centre 
(JRC). The authors conclude that:
The bioeconomy employed approximately 18.6 
million people in the EU-28 in 2014, generating 
turnover around EUR 2.2 trillion. Between 2008 and 
2014, employment in the European bioeconomy 
contracted, with the loss of nearly 2 million people 
employed. Agriculture and the manufacture of 
food, beverages and tobacco constituted three 
quarters of the jobs and two thirds of the turnover 
of the European Bioeconomy (Ronzon et al., 2017: 
7). 
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More detail on the numbers and metrics can be 
found in a report by Piotrowski et al (2018). The 
authors discovered that the biomass sectors were 
the most labour-intensive, particularly agriculture 
and fi shing. In terms of overall turnover, half of the 
2 trillion EUROS is accounted for by the food and 
beverage sector, a quarter from agriculture and 
forestry, and the remainder form what are defi ned 
as ‘biobased industries’ (which included plastics 
and chemicals, pharmaceuticals, paper products, 
forest-based industries , textiles, biofuels and bio-
energy). Again, we see how a very expansive and 
inclusive defi nition of bioeconomy can be used 
to make claims about current and future value. 
Disentangling from these figures the specific 
contributions of, say, advanced life sciences, and 
discounting what might be categorised as old or 
conventional biological activities or processes is 
not possible. The bioeconomy therefore becomes 
a catch-all term for an array of practices, activities 
and economic sectors that, together, are shown 
to generate value,  support national competitive-
ness, and solve grand global challenges. 
 
Discussion and Conclusions: 
New Approaches to 
Measurement and Value
What all these national and regional reports and 
strategies exemplify is how measurement, and the 
application of diff erent tools and metrics, can be 
used to drive diff erent narratives about the scale, 
scope, and value of the bioeconomy and its con-
stitutive activities and practices. Most advanced 
nations attempt to measure their bioeconomies 
and evaluate their national competitiveness. So 
we have Dutch estimates of the size of its Bio-
business (Heijman, 2016), and German attempts 
to measure the bioeconomy within the general 
economy (EŅ en et al., 2016). The idea of a vibrant 
bioeconomy is of strategic importance for nations 
and regions as they justify public investments in 
life sciences and industrial biotechnology. 
What is interesting in all these reports, which 
have a performative role in shaping industrial 
strategy, is that they operate with diff erent metrics 
for evaluation, making cross-country comparisons 
diffi  cult. Also, they adopt a very narrow defi ni-
tion of value; one linked inextricably to crude 
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ability, employment, GDP etc. If we take some of 
these crude economic metrics at face value, they 
suggest that the supposed biotechnology revo-
lution is not perhaps as revolutionary and profi t-
able as has been assumed; instead being based 
on unfulfi lled expectations driven by promissory 
discourses. As Birch argues, despite the global 
biotechnology industry increasing its market capi-
talization over time,
… in 2014 the life sciences sector was neither 
producing proportionally more products and 
services nor proportionally higher revenues than 
four or fi ve years earlier … [This illustrates] how 
uncertain and volatile value and valuations are in 
the bio-economy, and how disassociated they can 
often seem to be from the development of new 
products and services (Birch 2017: 2) 
Birch is interested in this contradiction between 
the high fi nancial valuations placed on the bio-
technology sector - partly sustained by reports 
suggesting the size and contribution of the bio-
economy is growing - and the failure of this to 
engender the products that public investments in 
biotechnology continually promise are imminent. 
One answer is that current value is simply based 
on the promissory visions and expectations of 
future economic returns from products, and this 
is what interests many scholars focused on bio-
value and the commodifi cation processes under-
lying the neoliberal bioeconomy. However, Birch’s 
argument is that we need to look beyond this to 
the ‘assetisation’ processes; that is the fi nancial 
technologies, knowledges, and practices that 
enable things to be transformed into assets and 
generate value. This leads him to consider value 
and valuation beyond the intrinsic or latent prop-
erties of the tangible biological objects them-
selves, or their related intangible products such as 
IP, which would be consistent with a commodity-
based analysis. Instead, he looks at the fi nancial 
valuation of the fi rms themselves, and their assets, 
arguing this is ultimately where the value is real-
ised (Birch 2017: 3). The outcome of this analysis 
is that “… value is constituted primarily by the 
social pracƟ ces of the political-economic actors 
who confi gure the fi nancial value and valuation of 
fi rms” (Birch 2017: 3). 
16
Science & Technology Studies XX(X)
While this approach is still focused primarily 
on value in a commercial/economic sense, 
opening up value to include the social practices 
of valuation enables us to think about the 
bioeconomy in a more interesting and sophisti-
cated way. This approach begs the question of 
whether the value allocated to the bioeconomy 
by diff erent actors, and the transformative activi-
ties and ways of organising research that have 
been precipitated by governments, policymakers, 
and industry, should be evaluated primarily 
through crude economic metrics, whether that be 
commodity or asset value. The fi eld of valuation 
studies (Helgesson and Muniesa 2013) shows we 
can capture both the objective and subjective 
elements of value and make better sense of the 
economic and noneconomic evaluation practices 
that frame diff erent accounts of benefi t and worth 
(Lamont, 2012). A broader, inclusive approach 
to value forces us to consider the multiple ways 
in which economic and non-economic value is 
enacted and performed in diff erent professional 
and social contexts (MiƩ ra, 2016; Stark, 2009). 
In the context of the bioeconomy, this 
approach to value enables us to illuminate the 
transformational changes that political projects, 
driven by advances in science and technology, 
have had on numerous industrial sectors and the 
ways in which their R&D is organised. It moves 
beyond narrow questions about whether the life 
sciences are meeting their early promise and satis-
fying expectations of delivering new products 
and economic returns, to looking at how interdis-
ciplinary and collaborative practices are emerging 
alongside new business models and value systems 
in an attempt to make advanced biology work to 
solve global problems. 
Policymakers, industrialists, scientists, publics, 
and a whole range of other stakeholders are 
concerned about the value and worth of innova-
tion in the health, agriculture, and environmental 
sectors, as our literature analysis and critical review 
of offi  cial reports has shown. Nevertheless, meas-
urement does guide behaviour, and attempts to 
talk about the bioeconomy as if its objects and 
practices were simple to define and measure 
can obscure as much as they reveal. As we have 
shown, the concept can appear meaningless 
given the diverse inclusion and exclusion criteria, 
which can aff ect estimations of value and worth. 
Of course, it is important to note that this strategy 
has been very successful  as a political project, and 
ensured resources have been allocated to sectors 
and organisations that have sought to enact these 
promises, hopes, and expectations. The trends in 
the science and social science literatures that we 
identifi ed, particularly the ways in which diff erent 
disciplines have focused on very diff erent sectors 
and application areas, further highlights the 
complexity and diversity of framing. The scien-
tifi c papers tend to mirror policy accounts that 
see the bioeconomy rooted in issues of sustain-
ability, with the social sciences more critical of 
bioeconomy and likely to reference green and red 
biotechnology as their key examples of commodi-
fi cation and assetisation processes. 
To conclude, we have attempted in this paper 
to trace the emergence and evolution of the 
concept of bioeconomy and show how it has 
been framed and used strategically by various 
constituencies as a political, scientifi c/technolog-
ical, and economic project to meet regional and 
global challenges. Our starting point was to ask: 
what is the bioeconomy, how has it been used in 
diff erent fi elds, and how might it be best under-
stood and valued?  It turned out that the answer 
to the last part, which is a normative question, is 
dependent on the answers to the fi rst part. How 
the bioeconomy is defined, both formally and 
informally, and what activities and practices are 
considered to be its immanent features, deter-
mines its scale, scope, and ultimately the value 
that diff erent stakeholders place on it. Neverthe-
less, by critiquing the concept of bioeconomy and 
the valuation tools and calculative devices used to 
measure it, we have shown that a broader concep-
tualisation of value that takes seriously underlying 
social practices, would perhaps better inform our 
understanding of the contributions made by the 
diff erent sectors within the bioeconomy. 
While it might be meaningless as a broad and 
highly inclusive concept, the bioeconomy, as a 
distinct economic regime that captures the new 
activities and practices of advanced biotech-
nology, can be studied in a meaningful and 
useful way. However, to do so, we need far more 
precision in the measurement tools we use; be 
highly cautious of reports that use inappropriate 
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inclusion or exclusion criteria that often artifi cially 
infl ate the economic contributions of the bioec-
onomy; and we perhaps need to stop prioritising 
white biotechnology as the key driver. We have 
shown that doing so obfuscates or downplays the 
important contributions of red and green biotech-
nology, and also elides the fact that benefi ts and 
limitations, including accounts of value, may vary 
between the diff erent categories. 
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